Unique Capabilities at PTS
Access to R&D personnel with expertise in:
01 - Post-polymerization modification of polymers by introduction of functional groups for controlled and orthogonal couplings.
Synthesis of different modified linear polymeric architectures based on polyglutamates and PEG
Our methodology allows for the incorporation of various functionalities by “post?polymerization modification”, thereby forming different reactive groups in the side chains of the polymers. This functionalization strategy allows adjustment of the pharmacological properties of each case to the use thereof in drugs or molecular imaging agents with therapeutic and/or diagnostic application.
02 - Taylor-made Polymer-based Drug Delivery Systems for Therapeutic, Imaging or Dermocosmetic applications
Polymer Chemistry: Development of novel biodegradable polymeric carriers with defined architecture (linear, block-copolymers, star polymers). Synthesis and exhaustive characterization:
- To be used for intracellular or extracellular drug delivery of Low Mw drugs, peptides, proteins and siRNAs
- Also molecular diagnostics (probe conjugation)
- Development of ‘New Chemical Entities’ with improved therapeutic value starting from either new discovered or well-known drugs with specific limitations (solubility, pharmacokinetics, etc)
- Rational design of nanoconjugates, mainly focused on the linking chemistry.
- Polymer combination therapy, looking at drug synergism or specific targeting.
01- Gel Permeation Chromatography
02- Dynamic Light Scattering
04- Circular Dichroism
05- H-NMR analysis
01- Endocytosis / Cell trafficking
(Qualitative and Quantitative methods)
02- Protein Expression analysis by western blot
03- Cell viability/Cytotoxicity
04- Cell viability/Cytotoxicity
Existing Biological Barriers for Nucleic Acid Delivery
- Nuclease degradation
- Low half-life
- Negatively charged
- Hydrophilic character
- Difficulties to cross the plasma membrane
PGA-based nucleic-acid-delivery systems are able to bind to nucleic acids, protect the nucleic acids from enzymatic degradation, promote cellular uptake and promote nuclear entry of the pDNA.
Please contact firstname.lastname@example.org to request an estimate.
GMP facilities: The facilities have been designed according to GMP standards, required for the manufacture of sterile products (eye drops, injectable, vaccines, cell therapy, gene therapy and tissue engineering, etc.).
Animal facility: Our Animal Facility is registered as Breeding, user and Supplier Center for Experimentation with Animals with no. ES 250 0001 002 and it is made up of qualified and accredited personnel in Laboratory Animal Science.
H1 -NMR: Equipment and knowledge for the identification, quantification and structural determination of all kind of chemical compounds.
Stem Cell Bank; Cytomics; Screening Platform; Confocal Microscopy; Proteomics